SurModics, Inc. Earnings Conference Call (Q4 2009)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other Nov 4 Calls Today's Calls

Call Details SurModics, Inc. Earnings Conference Call (Q4 2009) Wed, Nov 4, 2009, 5:00 pm Eastern Listen to the archived event audio About SurModics, Inc. (NasdaqGS:SRDX) SurModics, Inc. engages in the development, manufacture, and sale of surface modification and drug delivery technologies to the healthcare industry. The company operates in three segments: Drug Delivery, Hydrophilic and Other, and In Vitro. The Drug Delivery segment contains the Drug Delivery business unit, which offers technologies to site-specific delivery of drugs; the Ophthalmology business unit that provides treatment for eye diseases, such as age-related macular degeneration and diabetic macular edema; and the Brookwood Pharmaceuticals unit, which offers proprietary polymer-based technologies. The Hydrophilic and Other segment consists of three business units comprising the Hydrophilic Technologies business unit, which focuses on enhancing medical devices with lubricious coatings that facilitate their placement and maneuverability in the body; the Regenerative Technologies business unit that develops platforms to augment or replace tissue/organ function, or to modify medical devices to facilitate tissue/organ recovery through natural repair mechanisms; and the Orthopedics business unit, which provides solutions for orthopedics patients using proven surmodics technologies, and creates new technology solutions to existing patient care gaps in the orthopedics field. The In Vitro segment contains the In Vitro Technologies business unit, which offers microarray slide technologies, stabilization products, antigens, and substrates for immunoassay diagnostics tests, in vitro diagnostic format technology, and synthetic ECM cell culture products. The company markets its technologies and products in the United States and internationally. It has collaboration agreements with Donaldson Company, Inc. for the development of synthetic ECM cell culture products; and Merck & Co., Inc. for development and commercialization of products incorporating the company’s I-vation platform. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota. More Info: Quote | Chart | News | Profile | Reports | Research | SEC | Msgs | Insider | Financials | Analyst Ratings